Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals5.61%+1.00 ppBiotechnology2.57%+0.50 ppManaged Health Care2.50%+0.40 ppHealth Care Supplies0.18%-0.10 ppHealth Care Distributors0.39%+0.10 ppLife Sciences Tools & Services2.06%+0.06 ppHealth Care Facilities0.22%-0.03 ppHealth Care Equipment3.11%-0.02 ppHealth Care Services0.93%+0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.57%
Industry change · 12M
+0.50 pp
Biotechnology · contribution
+0.495 pp
Company participation
75%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
May 2022 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $260.4bn | 0.938% | +0.031 pp | +0.222 pp | +35.8% | Yes |
| Moderna → MRNA | United States | $57.8bn | 0.208% | -0.006 pp | +0.208 pp | -21.4% | No |
| Regeneron Pharmaceuticals → REGN | United States | $62.5bn | 0.225% | +0.023 pp | +0.056 pp | +32.3% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $68.7bn | 0.247% | +0.044 pp | +0.054 pp | +28.8% | Yes |
| Biogen → BIIB | United States | $29.3bn | 0.105% | -0.002 pp | -0.039 pp | -25.2% | No |
| Incyte → INCY | United States | $16.8bn | 0.061% | +0.008 pp | -0.005 pp | -9.4% | Yes |
| Amgen → AMGN | United States | $137.2bn | 0.494% | +0.056 pp | +0.004 pp | +11.5% | Yes |
| Gilead Sciences → GILD | United States | $81.3bn | 0.293% | +0.030 pp | -0.004 pp | +2.4% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.